CurifyLabs Raises $14M for Pharmacy-Based Personalized Medicine
Health technology firm CurifyLabs has secured $14 million in Series A funding to expand its automated system for producing personalized medications within pharmacies.
Helsinki-based CurifyLabs has announced a $14 million Series A funding round, co-led by Sandwater and HealthCap, with participation from Tesi, Lifeline Ventures, and U.S. customers. The company, which also has operations in Jacksonville, Florida, plans to use the investment to expand its presence in the United States, strengthen its supply chain, enhance customer support, and accelerate product development.
CurifyLabs' core offering is the Compounding System Solution (CSS), a platform that integrates proprietary software with GMP-manufactured excipient bases and 3D printing hardware to automate the process of pharmacy compounding. This system aims to deliver customized medication doses and forms with greater speed and accuracy compared to traditional manual methods, and it includes integrated quality control measures. The technology is currently in use across pharmacies in 21 U.S. states and throughout Europe, processing thousands of doses daily.
A portion of the new funding will be dedicated to advancing the CurifyLabs platform, including its recently introduced PharmaPrinter Aurum. This device reportedly compounds medications up to nine times faster than manual workflows. The PharmaPrinter Aurum holds ISO 13485 certification and is designed to meet FDA 503A/503B standards for non-sterile compounding, a crucial aspect as the company increases its U.S. operations.
The investment reflects growing investor interest in pharmaceutical additive manufacturing focused on personalized dosing. CurifyLabs differentiates itself by automating medication compounding directly within pharmacies, rather than developing new drugs. This funding will support the scaling of the supply chain and the necessary U.S. market expansion for this model.
This development highlights the increasing application of additive manufacturing in personalized medicine, specifically within the pharmaceutical compounding sector. By automating and accelerating the production of customized doses directly at the pharmacy level, CurifyLabs is addressing the need for more efficient and precise medication delivery. This aligns with the broader industry trend of leveraging AM for tailored healthcare solutions, moving beyond traditional manufacturing paradigms to meet individual patient needs.
Edited by the news editor with AI from the original report — please refer to the original source.